This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	Checkpoint kinase 1 (CHK1)	<p>Studies in mice suggest that inhibiting CHK1 could increase the efficacy of oncolytic adenoviral therapies for ovarian cancer. In xenograft mice with ovarian cancer cell line tumors, injection of a CHK1 inhibitor plus an oncolytic adenovirus decreased tumor volume compared with injection of either agent alone. Next steps could include testing the combination of CHK1 inhibitors and oncolytic adenoviruses in Phase I/II trials in ovarian cancer.</p> <p>Eli Lilly and Co's IC83, a CHK1 inhibitor, is in Phase I/II testing for cancer.</p> <p>SciBX 4(13); doi:10.1038/scibx.2011.369 Published online March 31, 2011</p>	Patent and licensing status undisclosed	<p>Connell, C.M. <i>et al. J. Clin. Invest.</i>; published online March 7, 2011; doi:10.1172/JCI43976</p> <p>Contact: Iain A. McNeish, Barts and the London School of Medicine and Dentistry, London, U.K. e-mail: i.a.mcneish@qmul.ac.uk</p>